BRISTOL-MYERS SQUIBB COMPANY Contract with Customer, Performance Obligation Satisfied in Previous Period
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Contract with Customer, Performance Obligation Satisfied in Previous Period of $356.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes
us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY contract with customer, performance obligation satisfied in previous period for the quarter ending 2026-06-30 was $356.00M, a 54.78% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY contract with customer, performance obligation satisfied in previous period for the quarter ending 2026-03-31 was $221.00M, a 50.23% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY contract with customer, performance obligation satisfied in previous period for the quarter ending 2025-12-31 was $308.00M, a 2.33% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY contract with customer, performance obligation satisfied in previous period for the quarter ending 2025-09-30 was $318.00M, a 33.61% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY contract with customer, performance obligation satisfied in previous period for fiscal 2025 was $1.30B, a 63.11% increase from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY contract with customer, performance obligation satisfied in previous period for fiscal 2024 was $797.00M, a 72.51% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY contract with customer, performance obligation satisfied in previous period for fiscal 2023 was $462.00M, a 16.91% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY contract with customer, performance obligation satisfied in previous period for fiscal 2022 was $556.00M, a 0.89% decline from fiscal 2021.
| Period end | Contract with Customer, Performance Obligation Satisfied in Previous Period 3 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 6 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 9 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | $356.00M 10-Q · filed 2026-07-30 | $577.00M 10-Q · filed 2026-07-30 | $885.00M derived: sum of 3 quarters · filed 2026-07-30 | $1.20B derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $221.00M 10-Q · filed 2026-04-30 | $529.00M derived: sum of 2 quarters · filed 2026-04-30 | $847.00M derived: sum of 3 quarters · filed 2026-04-30 | $1.08B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $308.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $626.00M derived: sum of 2 quarters · filed 2026-02-11 | $856.00M derived: sum of 3 quarters · filed 2026-07-30 | $1.30B 10-K · filed 2026-02-11 |
| 2025-09-30 | $318.00M 10-Q · filed 2025-10-30 | $548.00M derived: sum of 2 quarters · filed 2026-07-30 | $992.00M 10-Q · filed 2025-10-30 | $1.29B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $230.00M 10-Q · filed 2026-07-30 | $674.00M 10-Q · filed 2026-07-30 | $975.00M derived: sum of 3 quarters · filed 2026-07-30 | $1.21B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $444.00M 10-Q · filed 2026-04-30 | $745.00M derived: sum of 2 quarters · filed 2026-04-30 | $983.00M derived: sum of 3 quarters · filed 2026-04-30 | $1.06B derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $301.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $539.00M derived: sum of 2 quarters · filed 2026-02-11 | $615.00M derived: sum of 3 quarters · filed 2026-02-11 | $797.00M 10-K · filed 2026-02-11 |
| 2024-09-30 | $238.00M 10-Q · filed 2025-10-30 | $314.00M derived: sum of 2 quarters · filed 2025-10-30 | $496.00M 10-Q · filed 2025-10-30 | $603.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $76.00M 10-Q · filed 2025-07-31 | $258.00M 10-Q · filed 2025-07-31 | $365.00M derived: sum of 3 quarters · filed 2026-02-11 | $479.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $182.00M 10-Q · filed 2025-04-24 | $289.00M derived: sum of 2 quarters · filed 2026-02-11 | $403.00M derived: sum of 3 quarters · filed 2026-02-11 | $478.00M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $107.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $221.00M derived: sum of 2 quarters · filed 2026-02-11 | $296.00M derived: sum of 3 quarters · filed 2026-02-11 | $462.00M 10-K · filed 2026-02-11 |
| 2023-09-30 | $114.00M 10-Q · filed 2024-10-31 | $189.00M derived: sum of 2 quarters · filed 2024-10-31 | $355.00M 10-Q · filed 2024-10-31 | $461.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $75.00M 10-Q · filed 2024-07-26 | $241.00M 10-Q · filed 2024-07-26 | $347.00M derived: sum of 3 quarters · filed 2025-02-12 | $466.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $166.00M 10-Q · filed 2024-04-25 | $272.00M derived: sum of 2 quarters · filed 2025-02-12 | $391.00M derived: sum of 3 quarters · filed 2025-02-12 | $575.00M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $106.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $225.00M derived: sum of 2 quarters · filed 2025-02-12 | $409.00M derived: sum of 3 quarters · filed 2025-02-12 | $556.00M 10-K · filed 2025-02-12 |
| 2022-09-30 | $119.00M 10-Q · filed 2023-10-26 | $303.00M derived: sum of 2 quarters · filed 2023-10-26 | $450.00M 10-Q · filed 2023-10-26 | $548.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $184.00M 10-Q · filed 2023-07-27 | $331.00M 10-Q · filed 2023-07-27 | $429.00M derived: sum of 3 quarters · filed 2024-02-13 | $502.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $147.00M 10-Q · filed 2023-04-27 | $245.00M derived: sum of 2 quarters · filed 2024-02-13 | $318.00M derived: sum of 3 quarters · filed 2024-02-13 | $464.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $98.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $171.00M derived: sum of 2 quarters · filed 2024-02-13 | $317.00M derived: sum of 3 quarters · filed 2024-02-13 | $561.00M 10-K · filed 2024-02-13 |
| 2021-09-30 | $73.00M 10-Q · filed 2022-10-26 | $219.00M derived: sum of 2 quarters · filed 2022-10-26 | $463.00M 10-Q · filed 2022-10-26 | $581.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $146.00M 10-Q · filed 2022-07-27 | $430.00M 10-Q · filed 2022-07-27 | $508.00M derived: sum of 3 quarters · filed 2023-02-14 | $540.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $284.00M 10-Q · filed 2022-04-29 | $362.00M derived: sum of 2 quarters · filed 2023-02-14 | $394.00M derived: sum of 3 quarters · filed 2023-02-14 | $492.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $78.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $110.00M derived: sum of 2 quarters · filed 2023-02-14 | $208.00M derived: sum of 3 quarters · filed 2023-02-14 | $338.00M 10-K · filed 2023-02-14 |
| 2020-09-30 | $32.00M 10-Q · filed 2021-10-27 | $130.00M derived: sum of 2 quarters · filed 2021-10-27 | $260.00M 10-Q · filed 2021-10-27 | $330.00M derived: sum of 4 quarters · filed 2021-10-27 |
| 2020-06-30 | $98.00M 10-Q · filed 2021-07-28 | $228.00M 10-Q · filed 2021-07-28 | $298.00M derived: sum of 3 quarters · filed 2021-07-28 | $376.00M derived: sum of 4 quarters · filed 2021-07-28 |
| 2020-03-31 | $130.00M 10-Q · filed 2021-04-29 | $200.00M derived: sum of 2 quarters · filed 2021-04-29 | $278.00M derived: sum of 3 quarters · filed 2021-04-29 | $395.00M derived: sum of 4 quarters · filed 2021-04-29 |
| 2019-12-31 | $70.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $148.00M derived: sum of 2 quarters · filed 2021-02-10 | $265.00M derived: sum of 3 quarters · filed 2021-02-10 | $411.00M 10-K · filed 2021-02-10 |
| 2019-09-30 | $78.00M 10-Q · filed 2020-11-05 | $195.00M derived: sum of 2 quarters · filed 2020-11-05 | $341.00M 10-Q · filed 2020-11-05 | $439.00M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $117.00M 10-Q · filed 2020-08-06 | $264.00M 10-Q · filed 2020-08-06 | $361.00M derived: sum of 3 quarters · filed 2020-08-06 | $458.00M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $147.00M 10-Q · filed 2020-05-07 | $244.00M derived: sum of 2 quarters · filed 2020-05-07 | $341.00M derived: sum of 3 quarters · filed 2020-05-07 | $491.00M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $97.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $194.00M derived: sum of 2 quarters · filed 2020-02-24 | $344.00M derived: sum of 3 quarters · filed 2020-02-24 | $495.00M 10-K · filed 2020-02-24 |
| 2018-09-30 | $97.00M 10-Q · filed 2019-10-31 | $247.00M derived: sum of 2 quarters · filed 2019-10-31 | $398.00M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $150.00M 10-Q · filed 2019-07-25 | $300.00M 10-Q · filed 2019-07-25 | ||
| 2018-03-31 | $150.00M 10-Q · filed 2019-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |